Sangamo Therapeutics recently unveiled in-depth information from the registrational STAAR study on Fabry disease at the World Symposium in 2026. The study has provided crucial insights into the disease, covering key aspects and significant findings regarding treatment. Fabry disease impacts a substantial number of individuals globally, making the findings presented by Sangamo Therapeutics significant for the medical community. This presentation at the World Symposium underlines the importance of the research conducted by the company and sheds light on potential advancements in addressing Fabry disease.